215-OR: Safety and Performance of the Omnipod Hybrid Closed-Loop System in Young Children Aged 2-6 Years with Type 1 Diabetes
BUCKINGHAM B, FORLENZA G, SHERR J, GALDERISI A, EKHLASPOUR L, LEE J, OCONNOR J, DUMAIS B, HUYETT L, LAYNE J, LY T. 215-OR: Safety and Performance of the Omnipod Hybrid Closed-Loop System in Young Children Aged 2-6 Years with Type 1 Diabetes. Diabetes 2019, 68 DOI: 10.2337/db19-215-or.Peer-Reviewed Original ResearchDiabetes careMedtronic MiniMedSevere hypoglycemic eventsChildren Aged 2Advisory PanelYoung childrenMin/dAge 4.2Oral carbohydrateHybrid closed-loop systemHypoglycemic eventsGlycemic outcomesMean glucoseAged 2CGM useTherapy phaseInvestigational deviceType 1T1D therapyPercent timeMiniMedLexicon PharmaceuticalsCareUsual routineAdult participants1054-P: Insulin Sensitivity from Sensor and Pump Data in Youths with Type 1 Diabetes: Hybrid Closed-Loop Validation
SCHIAVON M, GALDERISI A, KRAEMER K, COBELLI C, MAN C, CENGIZ E. 1054-P: Insulin Sensitivity from Sensor and Pump Data in Youths with Type 1 Diabetes: Hybrid Closed-Loop Validation. Diabetes 2019, 68 DOI: 10.2337/db19-1054-p.Peer-Reviewed Original ResearchContinuous glucose monitoringInsulin sensitivityType 1 diabetesEuropean Medical Information FrameworkInsulin pump dataClosed-loop treatmentOral minimal modelMannKind CorporationSequential mealsInsulin therapyMeal studyPlasma glucoseGlycemic outcomesType 1Glucose monitoringSpeakers bureauMeal variationT1D.T1DInternational SocietyAdvisory PanelPump dataTreatmentSI indexDiabetes